AKBA Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
36.9M
-24.9%
49.1M
-8.2%
53.5M
-7.1%
57.6M
-1.9%
58.8M
Cost of Revenue
6.4M
-39.0%
10.4M
-15.2%
12.3M
-2.0%
12.5M
+33.6%
9.4M
Gross Profit
30.5M
-21.1%
38.7M
-6.2%
41.3M
-8.5%
45.1M
-8.7%
49.4M
Operating Expenses
42.0M
-6.7%
45.0M
-2.0%
46.0M
-14.3%
53.6M
+19.4%
44.9M
R&D
16.2M
+15.1%
14.1M
-5.1%
14.8M
-44.4%
26.6M
+78.3%
14.9M
SG&A
23.5M
-16.5%
28.2M
-7.4%
30.4M
+16.7%
26.1M
-10.3%
29.1M
Operating Income
-11462000
-81.2%
-6326000
-34.7%
-4696000
+45.1%
-8553000
-292.2%
4.4M
EBITDA
-10018000
-163.9%
-3796000
+13.1%
-4368000
+46.9%
-8232000
-272.7%
4.8M
Net Income
-14354000
-61.1%
-8908000
+1.6%
-9054000
+26.1%
-12244000
-2367.4%
540.0K
EPS (Basic)
$-0.05
-66.7%
$-0.03
+0.0%
$-0.03
+40.0%
$-0.05
$0.00
EPS (Diluted)
$-0.05
-66.7%
$-0.03
+0.0%
$-0.03
+40.0%
$-0.05
$0.00
Shares (Diluted)
276.9M
+2.7%
269.6M
+1.0%
267.0M
+10.6%
241.6M
-12.0%
274.4M
Akebia Therapeutics (AKBA) — Financials